65,437 trials
Gonococcal Infection
Primary: The Proportion of Participants That Become Infected With Individual N. Gonorrhoeae Strains in Non-competitive Infections — 0.80; 1.00 proportion of participants — p=1.000
Covid19
Primary: Mortality — 2; 10 participants
Opioid-use Disorder
Primary: Recruitment Rate — 3; 12; 5 Participants
Eating Disorders
Primary: Magnetic Resonance Imaging Scans — 2.98; 2.96 mm — p=.03
HIV-1 Infection
Primary: Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE) — 0 percentage of participants
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Number of Participants With Complete Response (CR) — 1 Participants
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
B-cell Chronic Lymphocytic Leukemia
Primary: Overall Survival (OS) — 95.09; 73.28 Months — p=0.276
HIV Infections
Primary: Pharmacokinetic (PK) Parameter: Single-dose Area-under-the-curve (AUC0-∞) of Doravirine (DOR) (Cohort 1) — 34.8 µM*hr
COVID-19
Primary: Safety of Clazakizumab for the Treatment of Patients With COVID-19 Disease — 3; 3; 6; 8 Adverse Events — p=0.10
Fanconi Anemia
Primary: Number of Participants Experiencing Graft Failure — 1; 0; 0; 0 Participants
Postpartum Depression
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 4; 0 Participants
Smoking · Smoking Cessation · HIV
Primary: Number of Participants With Smoking Cessation — 3; 5; 7 Participants
Migraine Disorders
Primary: Migraine Days Per Month — -8; -4; -3; -3 migraine days per month
Advanced Refractory Left Ventricular Heart Failure
Primary: Survival — 61 percentage of patients who survived